Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Aptinyx brings in $65mm via Series A round

Executive Summary

Aptinyx Inc. (N-methyl-D-aspartic acid (NMDA) receptor modulators for neurological disorders) raised $65mm in a Series A round led by New Leaf Venture Partners, which was joined by other new backers Frazier Healthcare Partners, Longitude Capital, and Osage University Partners; other participants included returning seed investors Adams Street Partners, LVP Life Science Ventures, PathoCapital, Goudy Park Capital, Beecken Petty O'Keefe & Co., and Northwestern University. New Leaf, Frazier, and Longitude added members to the board.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies